Fig. 4From: The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysisForest plot of the adverse events between nivolumab combined with ipilimumab and nivolumab alone. a Any grade TRAEs. b Grade 3 or higher TRAEsBack to article page